Auteur: Luigi Lay

Roberto Adamo joined Novartis Vaccines in 2007 where he was later appointed Head of the Carbohydrate Chemistry Laboratory, and Leader of the Conjugation & Synthesis Platform. After the GSK acquisition of the company he became Preclinical Representative Leader of the Conjugation Platform. He is currently Technology and Project Leader at GSK, Italy. His research focuses on the synthesis of glycans, glycoconjugates and glyconanoparticles to be used for carbohydrate-based therapeutics. He has over 70 publications in the field including a book. He is the Associate editor of the Glycoconjugate Journal. Luigi Lay is full professor at the Department of Chemistry of the University of Milan. His research interests are focused on carbohydrate chemistry and the use of synthetic glycans to investigate their biological properties. He is author of 86 publications in the field and some book chapters.